Affibody-mediated PET imaging of HER3 expression in malignant tumours

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Rosestedt, Maria ^a   Andersson, Ken G ^b   Mitran, Bogdan ^a   Tolmachev, Vladimir ^a   Lofblom, John ^b   Orlova, Anna ^a   Ståhl, Stefan ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; GALLIUM; HYBRID PROTEIN; MOLECULAR PROBE; PROTEIN BINDING;

ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; HUMAN; ISOTOPE LABELING; METABOLISM; MOLECULAR PROBE; NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE; X-RAY COMPUTED TOMOGRAPHY; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GALLIUM RADIOISOTOPES; HETEROGRAFTS; HUMANS; ISOTOPE LABELING; MOLECULAR PROBES; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTOR, ERBB-3; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84945176046     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15226     Document Type: Article

References (49)

1. Baselga, J., Swain, S. M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9, 463-475 (2009).
2. Amin, D. N., Campbell, M. R., Moasser, M. M. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin. Cell Dev. Biol. 21, 944-950 (2010).
3. Ma, J., Lyu, H., Huang, J., Liu, B. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol. Cancer 13, 105 (2014).
4. Claus, J., Patel, G., Ng, T., Parker, P. J. A role for the pseudokinase HER3 in the acquired resistance against EGFR-and HER2-directed targeted therapy. Biochem. Soc. Trans. 42, 831-836 (2014).
5. Gala, K., Chandarlapaty, S. Molecular pathways: HER3 targeted therapy. Clin. Cancer Res. 20, 1410-1416 (2014).
6. Garrett, J. T. et al. Transcriptional and posttranslational upregulation of HER3 (ErbB3) compensates for inhibition of HER2 tyrosine kinase. Proc. Natl. Acad. Sci. USA 108, 5021-5026 (2011).
7. Hamburger, A. W. The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. J. Mammary Gland Biol. Neoplasia 13, 225-33 (2008).
8. Jathal, M. K., Chen, L., Mudryj, M., Ghosh, P. M. Targeting ErbB3: the new RTK(id) on the prostate cancer block. Immunol. Endocr. Metab. Agents Med. Chem. 11, 131-149 (2011).
9. Soler, M. et al. HER3 is required for the maintenance of neuregulin-dependent and-independent attributes of malignant progression in prostate cancer cells. Int. J. Cancer 125, 2565-2575 (2009).
10. Venkateswarlu, S., Dawson, D. M., St, Clair, P., Gupta, A., Willson, J. K., Brattain, M. G. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 21, 78-86 (2002).
11. Kawakami, H. et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget 5, 11847-11856 (2014).
12. Xie, T. et al. Pharmacological targeting of the pseudokinase Her3. Nat. Chem. Biol. 10, 1006-1012 (2014).
13. Aurisicchio, L., Marra, E., Roscilli, G., Mancini, R., Ciliberto, G. The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget. 3, 744-758 (2012).
14. Kol A. et al. HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting. Pharmacol. Ther. 143, 1-11 (2014).
15. Di Cosimo, S., Baselga, J. Management of breast cancer with targeted agents: importance of heterogeneity. Nat. Rev. Clin. Oncol. 7, 139-147 (2010).
16. Tolmachev, V., Stone-Elander, S., Orlova, A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol. 11, 992-1000 (2010).
17. Pecking, A. P., Bellet, D., Alberini, J. L. Immuno-SPET/CT and immuno-PET/CT: a step ahead to translational imaging. Clin. Exp. Metastasis 29, 847-852 (2012).
18. Terwisscha van Scheltinga, A. G. et al. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody Zr-RG7116. MAbs 6, 1051-1058 (2014).
19. Lofblom, J., Frejd, F. Y., Stahl, S. Non-immunoglobulin based protein scaffolds. Curr. Opin. Biotechnol. 22, 843-848 (2011).
20. Ahlgren, S., Tolmachev, V. Radionuclide molecular imaging using Affibody molecules. Curr. Pharm. Biotechnol. 11, 581-9 (2010).
21. Sorensen, J. et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J. Nucl. Med. 55, 730-735 (2014).
22. Sorensen, J. et al. Measuring HER2-expression in metastatic breast cancer using 68Ga-ABY025 PET/CT. Eur. J. Nucl. Med. Mol. Imaging 41(Suppl.2), S226 (2014).
23. Malm, M. et al. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar pffinity by position-directed error-prone PCR-like diversification. PLoS One 8, e62791 (2013).
24. Robinson, M. K. et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br. J. Cancer 99, 1415-1425 (2008).
25. The Human Protein Atlas database. http://www.proteinatlas.org. (Accessed: 19th May 2015).
26. Tolmachev, V., Tran, T. A., Rosik, D., Sjoberg, A., Abrahmsen, L., Orlova, A. Tumor targeting using Affibody molecules: an interplay of a target expression level, affinity and binding site composition. J. Nucl. Med. 53, 953-960 (2012).
27. Orlova, A. et al. Imaging of HER3-expressing xenografts in mice using a 99mTc(CO)3-HEHEHE-Zher3:08699 affibody molecule. Eur. J. Nucl. Med. Mol. Imaging 41, 1450-1459 (2014).
28. Orlova, A. et al. 99mTc(CO)3]+(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours. Eur. J. Nucl. Med. Mol. Imaging 40, 439-449 (2013).
29. Tolmachev, V. et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur. J. Nucl. Med. Mol. Imaging 37, 613-22 (2010).
30. Andersson K. G. et al. Comparative evaluation of 111In-labeled NOTA?conjugated affibody molecules for visualization of HER3 expression in malignant tumours. Oncol Rep 34, 1042-1048 (2015).
31. Fani, M., Andre, J. P., Maecke, H. R. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol. Imaging 3, 67-77 (2008).
32. Strand, J. et al. Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts. PLoS One 8, e70028 (2013).
33. Heskamp, S. et al. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J. Nucl. Med. 53, 146-53 (2012).
34. Razumienko, E. J., Scollard, D. A., Reilly, R. M. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. J. Nucl. Med. 53, 1943-1950 (2012).
35. Wehrenberg-Klee, E., Turker, N. S., Chang, B., Heidari, P., Mahmood, U. Development of a HER3 PET probe for breast cancer imaging. J. Nucl. Med. 55 (Suppl.1): s550 (2014).
36. Orlova, A., Wallberg, H., Stone-Elander, S., Tolmachev, V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J. Nucl. Med. 50, 417-25 (2009).
37. Malmberg, J., Sandstrom, M., Wester, K., Tolmachev, V., Orlova, A. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In-and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. Nucl. Med. Biol. 38, 1093-1102 (2011).
38. Honarvar, H. et al. Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX:1 affibody molecule. Int. J. Oncol. 46, 513-20 (2015).
39. Tolmachev, V. et al. Imaging of platelet-derived growth factor receptor ? expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591. J. Nucl. Med. 55, 294-300 (2014).
40. Tolmachev, V. et al. Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551. J. Nucl. Med. 53, 90-97 (2012).
41. Wallberg, H., Orlova, A. Slow internalization of anti-HER2 synthetic Affibody monomer 111In-DOTA-Zher2:342-pep2: Implications for development of labeled tracers. Cancer Biother. Radiopharm. 23, 435-42 (2008).
42. Tolmachev, V., Wallberg, H., Sandstrom, M., Hansson, M., Wennborg, A., Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur. J. Nucl. Med. Mol. Imaging 38, 531-539 (2011).
43. Broan, C. J. et al. Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononanetriacetate and of yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radioimmunotherapy. X-Ray molecular structure of the indium and gallium complexes of 1,4,7-triazacyclononane-1,4,7-triacetic acid. J. Chem. Soc., Perkin Trans. 2, 87-99 (1991).
44. Matthews, R. C. et al. Synthesis and structure of stable indium and gallium complexes of (R)-1,4,7-tris(2?-methylcarboxymethyl)-triazacyclononane. Polyhedron. 10, 1951-1953 (1991).
45. Ginj, M. et al. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting. Clin. Cancer Res. 14, 2019-2027 (2008).
46. Decristoforo, C. et al. 68Ga-and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur. J. Nucl. Med. Mol. Imaging. 35, 1507-1515 (2008).
47. Rolleman, E. J., Melis, M., Valkema, R., Boerman, O. C., Krenning, E. P., de Jong, M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur. J. Nucl. Med. Mol. Imaging. 37, 1018-31 (2010).
48. Vegt, E. et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J. Nucl. Med. 51, 1049-58 (2010).
49. Altai, M., Varasteh, Z., Andersson, K., Eek, A., Boerman, O., Orlova, A. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors. Cancer Biother. Radiopharm. 28, 187-95 (2013).